(Press-News.org) A new potential antibody therapy strategy which restricts the growth of treatment-resistant breast cancers has been developed by scientists.
The King’s College London discovery, published today, could provide new treatment options for some of the most aggressive forms of breast cancer. This may be particularly important for patients whose cancers no longer respond to existing therapies, as well as those with triple-negative breast cancer – a subtype which lacks the receptors which are common drug targets, where treatment choices remain very limited.
The team designed an antibody that not only attacks the tumour cells directly, but also harnesses the body’s own immune defences. The first of its kind ‘triple-engineered antibody’, latches onto cancer cells on one end and draws in immune cells on the other.
While researchers have been modifying antibodies to boost their ability to activate immune cells, highly effective ones to be used for the treatment of breast cancer are still needed. The Breast Cancer Now Research Unit at King’s College London has been at forefront of this research for more than a decade. The group focuses on studying the patient’s immune system with a view of designing and testing innovative antibodies able to activate the patient’s immune response.
In their latest study, laboratory experiments and animal models revealed the modified antibody bound immune cells more strongly compared to current treatments. This activated the immune cells already present in the tumour to attack it, limiting the growth of tumours in triple-negative and treatment-resistant breast cancers.
The researchers also found that the modified antibody activated immune cells circulating in the bloodstream, which could boost the body’s overall ability to detect and fight cancer.
First author Dr Alicia Chenoweth, from the Faculty of Life Sciences & Medicine at King’s College London, said: “By making a few key changes in the structure of the antibody, we found that it could activate the immune system much more powerfully than an unmodified antibody currently used in breast cancer treatment.
“Many of the immune cells in breast tumours are in a ‘suppressed’ state, difficult to activate with unmodified antibodies. We found our triple-engineered antibodies were not only able to activate these immune cells to kill the cancer cells, but shifted these immune cells to a more ‘activated’ state overall.”
Lead author Professor Sophia Karagiannis, expert in Translational Cancer Immunology and Immunotherapy at King’s College London, who led this study said: “By examining key immune cell receptors in breast tumours, including those tumours resistant to chemotherapy and immunotherapy, we have designed our antibody to make them interact better and harness the immune system in a way that has never been done or tested in cancer before.
“If it proves successful, it could stimulate the immune system directly and address the significant unmet need we see in treatment resistant cancers including triple-negative breast cancer.”
Triple-negative breast cancer accounts for around 15 per cent of all breast cancers. It is a subtype that lacks receptors for the hormones oestrogen and progesterone and the HER2 protein, which are often treatment targets in other subtypes of breast cancer. As it lacks these targets, standard hormone therapies and drugs that target HER2 are ineffective, leaving patients with fewer treatment options and a higher risk of recurrence.
HER2-positive cancers are often treated with drugs, which improve outcomes for many patients, but the development of resistance remains a clinical challenge.
Dr Simon Vincent, chief scientific officer at Breast Cancer Now, said: “This promising, early-stage research offers hope for more and better treatments for over 8,000 women who are diagnosed with triple negative breast cancer each year in the UK.
“We know how urgently these women need new treatment options, as this form of the disease can be more challenging to treat, may be more likely to return or spread in the first few years following treatment, and it affects younger women and black women more than other groups. By funding research like this, we’re driving progress towards ensuring everyone with breast cancer lives and lives well.”
The team is now working towards developing immune-active antibodies so that one day these can be tested in patients in clinical trials. Further laboratory work is underway to optimise the therapy, including extending how long the antibody lasts in the body and ensuring it can activate a broader range of immune cell types.
The research not only highlights the potential of this therapy for breast cancer patients but could be used in other cancers. One of the antibody targets is also present in ovarian and endometrial cancers, so the approach might have clinical potential for these diseases too.
The study was published in Cancer Research, a journal of the American Association for Cancer Research.
Notes to Editors
Funding:
Asda Tickled Pink fully funds Breast Cancer Now’s research unit at King’s College London, contributing over £1 million annually to advance knowledge of triple negative breast cancer - one of the hardest types to treat.
Industrial Partners:
SeromYx Systems, Inc., 299 Washington St, Ste D, Woburn, MA 01801 USA
Ludger, Ltd., Culham Campus, Abingdon, Oxfordshire OX14 3EB, United Kingdom; END
New antibody restricts the growth of aggressive and treatment-resistant breast cancers
2025-10-23
ELSE PRESS RELEASES FROM THIS DATE:
Newly discovered ‘super-Earth’ offers prime target in search for alien life
2025-10-23
UNIVERSITY PARK, Pa. — The discovery of a possible “super-Earth” less than 20 light-years from our own planet is offering scientists new hope in the hunt for other worlds that could harbor life, according to an international team including researchers from Penn State. They dubbed the exoplanet, named GJ 251 c, a “super-Earth” as data suggest it is almost four times as massive as the Earth, and likely to be rocky planet.
"We look for these types of planets because they are our best chance at finding life elsewhere,” said Suvrath Mahadevan, the Verne M. Willaman Professor of Astronomy at Penn State and co-author ...
Transport and dispersion of radioactive pollutant in the Northern South China Sea
2025-10-23
This study was led by Jinxiao Hou, Dr. Xiaolin Hou, and Dr. Yanyun Wang from the Institute of Earth Environment, Chinese Academy of Sciences. The northern offshore region of the South China Sea hosts one of the highest densities of nuclear power plants along China’s coastline. By systematically collecting seawater samples throughout this area and applying the laboratory’s well-established ultra-trace analytical techniques for ¹²⁹I and ¹²⁷I, the team measured the concentration levels and spatial distributions of both isotopes. By integrating observed ¹²⁹I/¹²⁷I atomic ...
Loneliness interventions help but are not a cure-all
2025-10-23
Interventions designed to reduce loneliness can be effective, but do not yet offer a complete solution to what is becoming a worldwide public health problem, according to research published by the American Psychological Association.
“Loneliness is now widely acknowledged as a serious public health concern linked to depression, anxiety, cardiovascular disease and even early mortality,” said lead author Mathias Lasgaard, PhD, of the Central Denmark Region and University of Southern Denmark. “Our findings provide strong evidence that interventions can make a difference, though their overall impact remains modest. Loneliness does not have a one-size-fits-all ...
Nearly 1 in 5 urinary tract infections linked to contaminated meat
2025-10-23
WASHINGTON (Oct. 23, 2025) — A new study estimates that nearly one in five urinary tract infections in Southern California may be caused by E. coli strains transmitted through contaminated meat – and pose a hidden foodborne risk to millions of people not just in California but across the US. The research, published in mBio, also found that people living in low-income neighborhoods are at the greatest risk.
“Urinary tract infections have long been considered a personal health issue, but our findings suggest that they are also a food safety problem,” said Lance B. Price, senior author of the ...
FAU Engineering researchers make great ‘strides’ in gait analysis technology
2025-10-23
A study from the College of Engineering and Computer Science and the Sensing Institute (I-SENSE) at Florida Atlantic University reveals that foot-mounted wearable sensors and a 3D depth camera can accurately measure how people walk – even in busy clinical environments – offering a powerful and more accessible alternative to traditional gait assessment tools.
Gait, the pattern of how a person walks, is an increasingly important marker of overall health, used in detecting fall risk, monitoring rehabilitation, and identifying ...
One step closer to quantum computers that work properly
2025-10-23
Quantum computers are computers that are much faster at performing some important types of computational tasks than many of today's machines. Sounds perfect, right?
But for now, the building blocks that perform the calculations in the quantum computer, so-called quantum bits or "qubits", are too unstable to make quantum processors that are large enough to be really useful.
"Quantum computers are completely dependent on qubits remaining stable in order to perform the special calculations they are designed for," says Jacob Benestad, who recently ...
Common toxin linked to liver disease
2025-10-23
LOS ANGELES — Liver disease is usually caused by one of three factors: alcohol consumption, fat buildup in the liver linked to obesity, diabetes and high cholesterol, or hepatitis B and C.
Now, a new study published in Liver International from Keck Medicine of USC reveals that tetrachloroethylene (PCE), a chemical used in dry cleaning and found in consumer products such as adhesives for arts and crafts, spot cleaners and stainless steel polish, may also be harmful to the liver.
Exposure to PCE was shown to triple the risk ...
Inaugural Jack Sarver Prize honors groundbreaking research by St. Louis, Dallas scientists
2025-10-23
DALLAS, Oct. 23, 2025 — Zainab Mahmoud, M.D., M.Sc., an assistant professor of medicine at Washington University School of Medicine in St. Louis, and Zhao Zhang, Ph.D., an assistant professor at the University of Texas (UT) Southwestern Medical Center in Dallas, will receive the inaugural Jack Sarver Prize in Clinical Science and Jack Sarver Prize in Basic Science, respectively, at the American Heart Association’ Scientific Sessions 2025. The meeting, to be held Nov. 7-10, 2025, in New Orleans, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular ...
Two abstracts using Bronchiectasis and NTM Research Registry data presented at CHEST 2025
2025-10-23
Miami (October 23, 2025) – The Bronchiectasis and NTM Association announced today that two abstracts using Bronchiectasis and NTM Research Registry data were presented at CHEST 2025, held October 19-22, 2025, in Chicago.
The abstracts are:
“The Relationship Between Baseline Severity of Bronchiectasis and Incident Non-Tuberculous Mycobacterial Infection: findings from the U.S. Bronchiectasis and NTM Research Registry,” which examined whether increased bronchiectasis severity was associated with an increased risk of NTM ...
Decades-old asthma theory challenged: Newly discovered molecules may be real drivers of disease
2025-10-23
CLEVELAND—For decades, scientists have thought they understood the biochemical machinery that causes asthma—inflammation in the lungs that constricts airways and makes it hard to breathe.
Molecules called “leukotrienes”—chemicals that get released from white blood cells when something irritates your airways or you inhale an allergen—were labeled the culprits. Medications have been developed to block the molecular cascade they initiate that leads to difficulty breathing.
But ...